Concepedia

Publication | Open Access

Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a<i>post hoc</i>analysis of the X-VeRT trial

DOIFull Paper Access

28

Citations

8

References

2015

Year

Stefan H. Hohnloser, Riccardo Cappato, Michael D. Ezekowitz, Thomas Evers, Kurtuluş Şahin, Paulus Kirchhof, Isabelle Ling Meng, Martin van Eickels, A. John Camm
EP Europace

Abstract

The use of rivaroxaban in the setting of cardioversion resulted in greater patient satisfaction and cost savings, compared with that of VKA.

References

YearCitations

Page 1